Human Surfactant from Amniotic Fluid in the Treatment of Respiratory Distress Syndrome
The major issue in surfactant substitution has been the availability of an efficient and safe preparate. At present the quantitative and especially the qualitative requirements of surfactant are unclear. The evaluation is complex because the severity of RDS varies widely. There are a number of possible preparates that function well both in vitro and in vivo in animals. The first and the best known was that used by Fujiwara et al. (1980). However, the suitability is ultimately evaluated on the basis of controlled trials comparing the outcome and the long-term follow-up.
KeywordsAmniotic Fluid Patent Ductus Arteriosus Hyaline Membrane Disease Natural Surfactant Exogenous Surfactant
Unable to display preview. Download preview PDF.
- Friedman WF, George BC (1984) Treatment of congestive heart failure by altering loading conditions of the heart. J Pediatr 106: 697–706Google Scholar
- Hallman M (1984) Antenatal diagnosis of lung maturity. In: Robertson B, Van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant. Elsevier, Amsterdam, pp 419–448Google Scholar